[go: up one dir, main page]

CA2368998A1 - Diffusion de sequences de proteines fonctionnelles par translocation de polypeptides - Google Patents

Diffusion de sequences de proteines fonctionnelles par translocation de polypeptides Download PDF

Info

Publication number
CA2368998A1
CA2368998A1 CA002368998A CA2368998A CA2368998A1 CA 2368998 A1 CA2368998 A1 CA 2368998A1 CA 002368998 A CA002368998 A CA 002368998A CA 2368998 A CA2368998 A CA 2368998A CA 2368998 A1 CA2368998 A1 CA 2368998A1
Authority
CA
Canada
Prior art keywords
cell
protein
target gene
translocating
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002368998A
Other languages
English (en)
Inventor
Brian Dalby
Robert P. Bennett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Technologies Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2368998A1 publication Critical patent/CA2368998A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des procédés de modulation d'un processus cellulaire par le contact d'une cellule en culture avec une molécule de modification de processus cellulaire fixée à un polypeptide de translocation. Par exemple, dans un mode de réalisation, une cellule en culture est transfectée avec un gène cible par le contact d'une cellule en culture avec un polynucléotide (contenant un gène cible) fixé à un polypeptide de translocation. Dans un autre mode de réalisation, l'expression d'un produit génique cible dans une cellule contenant un gène cible sous le contrôle d'un ou de plusieurs éléments de régulation est modulée par le contact de la cellule en culture avec un ou plusieurs agents de régulation fixés à un polypeptide de translocation. Ledit un ou lesdits plusieurs agents de régulation sont transloqués dans la cellule en culture et interagissent en son sein avec ledit un ou lesdits plusieurs éléments de régulation pour moduler l'expression du produit génique cible par la cellule.
CA002368998A 1999-03-31 2000-03-31 Diffusion de sequences de proteines fonctionnelles par translocation de polypeptides Abandoned CA2368998A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12746799P 1999-03-31 1999-03-31
US60/127,467 1999-03-31
PCT/US2000/008571 WO2000058488A2 (fr) 1999-03-31 2000-03-31 Diffusion de sequences de proteines fonctionnelles par translocation de polypeptides

Publications (1)

Publication Number Publication Date
CA2368998A1 true CA2368998A1 (fr) 2000-10-05

Family

ID=22430280

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002368998A Abandoned CA2368998A1 (fr) 1999-03-31 2000-03-31 Diffusion de sequences de proteines fonctionnelles par translocation de polypeptides

Country Status (5)

Country Link
EP (1) EP1165819A2 (fr)
JP (2) JP2002539839A (fr)
AU (2) AU775001B2 (fr)
CA (1) CA2368998A1 (fr)
WO (1) WO2000058488A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
DK1129064T3 (da) 1998-11-12 2008-04-28 Invitrogen Corp Transfektionsreagenser
DE19933492B4 (de) * 1999-07-16 2008-01-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Konjugat zur Vermittlung eines zell-, kompartiment- oder membranspezifischen Transports von Wirksubstanzen, Verfahren zu dessen Herstellung und dessen Verwendung
WO2001049832A2 (fr) * 2000-01-07 2001-07-12 Artemis Pharmaceuticals Gmbh Transduction de recombinases pour ciblage genetique inductible
AU2001288955A1 (en) * 2000-09-07 2002-03-22 Vanderbilt University Genome engineering by cell-permeable dna site-specific recombinases
FR2816845B1 (fr) 2000-11-20 2006-10-20 Centre Nat Rech Scient Vecteurs de transport a travers un epithelium a jonctions serrees
DE10290072D2 (de) * 2001-01-10 2003-12-18 Amaxa Gmbh Modulare Transfektionssysteme
US7364750B2 (en) 2001-04-30 2008-04-29 The University Of British Columbia Autogene nucleic acids encoding a secretable RNA polymerase
EP1354952A1 (fr) * 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Peptides dérivés de Smac, comme agents thérapeutiques contre le cancer et les maladies autoimmunes
EP1354953A1 (fr) * 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Peptides dérivés de Smac, comme agents thérapeutoques contre le cancer et les maladies auto-immunes
WO2003086470A2 (fr) * 2002-04-17 2003-10-23 Deutsches Krebsforschungszentrum Peptides smac comme agents therapeutiques contre le cancer et les maladies auto-immunes
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
EP2418281B1 (fr) * 2003-10-24 2016-06-01 Gencia Corporation Procédés et compositions pour l'administration de polynucléotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US20050209147A1 (en) * 2004-01-16 2005-09-22 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of RhoA signaling
GB0515115D0 (en) * 2005-07-22 2005-08-31 Isogenica Ltd Peptide characterisation
DE102008051708A1 (de) * 2008-10-06 2010-04-08 Universität Tübingen Ortsspezifische Rekombination zur Genaktivierung in genetischen Systemen
EP2612918A1 (fr) 2012-01-06 2013-07-10 BASF Plant Science Company GmbH Recombinaison in planta
CA2939541C (fr) * 2014-02-14 2022-11-08 Symvivo Corporation Proteines hybrides et leurs utilisations
WO2016011203A1 (fr) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions comprenant des agrégats lipidiques et procédés d'administration efficace de molécules dans des cellules
CN115843269A (zh) 2020-03-26 2023-03-24 拉利玛生物医药公司 用于细胞器特异性蛋白递送的分子

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU727531B2 (en) * 1995-07-25 2000-12-14 Crucell Holland B.V. Methods and means for targeted gene delivery
CA2227786A1 (fr) * 1995-07-28 1997-02-13 Marie Curie Cancer Care Proteines de transport et leur utilisation
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
EP0998577B1 (fr) * 1997-07-24 2004-10-27 Perseptive Biosystems, Inc. Conjugues de peptides transporteurs et analogues d'acides nucleiques ainsi que leur utilisation
JP2001511356A (ja) * 1997-07-28 2001-08-14 ミネソタ マイニング アンド マニュファクチャリング カンパニー 胞子発芽培地
GB9718609D0 (en) * 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
GB9723825D0 (en) * 1997-11-11 1998-01-07 Actinova Ltd Nuclear targeting by means of bacterial proteins

Also Published As

Publication number Publication date
AU2004220829A1 (en) 2004-11-18
AU775001B2 (en) 2004-07-15
AU4055500A (en) 2000-10-16
EP1165819A2 (fr) 2002-01-02
WO2000058488A2 (fr) 2000-10-05
JP2002539839A (ja) 2002-11-26
JP2005323619A (ja) 2005-11-24
WO2000058488A3 (fr) 2001-01-18

Similar Documents

Publication Publication Date Title
US20050208657A1 (en) Delivery of functional protein sequences by translocating polypeptides
AU775001B2 (en) Delivery of functional protein sequences by translocating polypeptides
US12202861B2 (en) Inducible, tunable, and multiplex human gene regulation using CRISPR-Cpf1
AU2022200851B2 (en) Using nucleosome interacting protein domains to enhance targeted genome modification
JP7109547B2 (ja) 真核ゲノム修飾のための操作されたＣａｓ９システム
WO1999013719A1 (fr) Modification chimique d'adn a l'aide de conjugues d'acide nucleique peptidique
EP1114172B1 (fr) Procede de transfert pour la localisation cellulaire specifique d'acides nucleiques
WO2020069029A1 (fr) Nouvelles nucléases crispr
AU2020221274B2 (en) Crispr/Cas fusion proteins and systems
US20050042603A1 (en) Compositions and methods for peptide-assisted transfection
Neves et al. Intracellular fate and nuclear targeting of plasmid DNA
CA3167684A1 (fr) Plateforme de distribution de composition d'echafaudage de nuclease
US20250179452A1 (en) Systems and methods for transposing cargo nucleotide sequences
JP2025510006A (ja) カーゴヌクレオチド配列を転位するための系及び方法
EP4413140B1 (fr) Système d'édition de génome synthétique
CN118318044A (zh) 合成的基因组编辑系统

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead